Genmab A/S
GMAB33.420USD
-0.300-0.89%
收盤 12/26, 16:00（美東）報價延遲15分鐘
20.58B總市值
14.14本益比TTM
關於 Genmab A/S 公司
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S簡介
公司代碼GMAB
公司名稱Genmab A/S
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
員工數量2682
證券類型Depository Receipt
年結日Oct 01
公司地址Carl Jacobsens Vej 30
城市VALBY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Denmark
郵編2500
電話4570202728
網址https://www.genmab.com/
公司代碼GMAB
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
Genmab A/S公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
由於公司未披露，未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
其他
94.64%
持股股東
持股股東
佔比
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
其他
94.64%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
4.59%
Investment Advisor
3.46%
Hedge Fund
1.96%
Research Firm
0.19%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
Venture Capital
0.01%
其他
89.71%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
Parametric Portfolio Associates LLC
1.19M
0.19%
-6.41K
-0.54%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
查看更多
Tema Oncology ETF
佔比4.2%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.02%
WisdomTree BioRevolution Fund
佔比1.31%
iShares Biotechnology ETF
佔比1.15%
AB Disruptors ETF
佔比0.69%
JPMorgan Healthcare Leaders ETF
佔比0.28%
First Trust NASDAQ BuyWrite Income ETF
佔比0.26%
ProShares Ultra Nasdaq Biotechnology
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.12%
ActivePassive International Equity ETF
佔比0.12%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Genmab A/S的前五大股東是誰？
Genmab A/S的前五大股東如下：
Orbis Investment Management Ltd.持有股份：7.92M佔總股份比例：1.29%。
AllianceBernstein L.P.持有股份：10.66M佔總股份比例：1.73%。
Arrowstreet Capital, Limited Partnership持有股份：3.45M佔總股份比例：0.56%。
Harding Loevner LP持有股份：2.92M佔總股份比例：0.48%。
Two Sigma Investments, LP持有股份：3.44M佔總股份比例：0.56%。
Orbis Investment Management Ltd.持有股份：7.92M佔總股份比例：1.29%。
AllianceBernstein L.P.持有股份：10.66M佔總股份比例：1.73%。
Arrowstreet Capital, Limited Partnership持有股份：3.45M佔總股份比例：0.56%。
Harding Loevner LP持有股份：2.92M佔總股份比例：0.48%。
Two Sigma Investments, LP持有股份：3.44M佔總股份比例：0.56%。
Genmab A/S的前三大股東類型是什麼？
Genmab A/S 的前三大股東類型分別是：
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
有多少機構持有Genmab A/S(GMAB)的股份？
截至2025Q3，共有515家機構持有Genmab A/S的股份，合計持有的股份價值約為64.81M，占公司總股份的10.54% 。與2025Q2相比，機構持股有所增加，增幅為0.23%。
哪個業務部門對Genmab A/S的收入貢獻最大？
在FY2025Q2，Royalties業務部門對Genmab A/S的收入貢獻最大，創收789.00M，占總收入的85.30% 。
